Skip to main content
STVN
NYSE Industrial Applications And Services

Stevanato Group Q2 Revenue Climbs 8%, Divests Balda C. Brewer, and Lifts Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$19.65
Mkt Cap
$5.365B
52W Low
$12.89
52W High
$28
52W Position info
52% above low
Off High info
30% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

STVN sits 52% above its 52-week low of $12.89 on elevated volume (2.7× avg).

Summary

Stevanato Group posted Q2 2026 revenue of €302M, an 8% increase, expanded its adjusted EBITDA margin to 26%, and raised full-year guidance. The company also completed the sale of its California-based Balda C. Brewer subsidiary and announced European marketing authorizations for its Alina® pen injector platform.

Updates

  1. · SEC 6-K — Q2 net profit was €22.96M, down from €29.70M a year earlier, due to a €12.2M loss on the Balda C. Brewer sale and higher income taxes of €15.16M.


Key Events · Earnings and Guidance · STVN

  • Q2 Revenue and Margin Beat

    Revenue rose 8% to €302.0M, with high-value solutions surging 16% to €135.9M, now 45% of the total. Adjusted EBITDA margin expanded 280 basis points to 26.0%, thanks to operational improvements at the Fishers and Latina plants.

  • Balda C. Brewer Divestiture

    The sale of the California-based subsidiary closed on June 30, 2026, resulting in a €12.2M loss. The divested business was on track for roughly €30M in FY2026 revenue; the transaction is expected to be accretive to full-year margins.

  • Raised Full-Year Guidance

    FY2026 revenue guidance was narrowed to €1.260B–€1.280B (from €1.260B–€1.290B), adjusted EBITDA was raised to €335.0M–€345.2M, and adjusted diluted EPS was tightened to €0.60–€0.62, reflecting improved currency translation and stronger organic growth.

  • Alina® Pen Platform Commercial Milestone

    A customer secured European marketing authorizations for a liraglutide-based therapy using Stevanato's Alina® pen injector and cartridge technology, validating the integrated drug delivery platform in the GLP-1 market.


Analysis · STVN · Industrial Applications And Services

A solid quarter for Stevanato featured 8% revenue growth and a 280-basis-point expansion in adjusted EBITDA margin, fueled by high-value solutions. While the divestiture of Balda C. Brewer triggered a one-time €12.2M loss, it removes a lower-margin business and is expected to be margin-accretive. Management raised the midpoint of adjusted EBITDA guidance and narrowed EPS, underscoring confidence in the core drug containment and delivery operations. The European marketing authorizations for the Alina® pen injector platform represent a major commercial milestone, embedding Stevanato's integrated cartridge and device capabilities in a GLP-1 therapy—a high-growth market.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STVN was trading at $19.65 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $12.89 to $28.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STVN - Latest Insights

STVN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.38
Real-time Price: $15.25 info
Change: +$1.87 (+14%) info
Market Cap: $4.163B info
STVN
Nov 04, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $15.25 info
Change: +$1.09 (+8%) info
Market Cap: $4.163B info
STVN
Nov 03, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.46
Real-time Price: $15.25 info
Change: +$0.7897 (+5%) info
Market Cap: $4.163B info
STVN
Nov 03, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $15.25 info
Change: +$1.15 (+8%) info
Market Cap: $4.163B info
STVN
Nov 03, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.74
Real-time Price: $15.25 info
Change: -$4.49 (-23%) info
Market Cap: $4.163B info